A potential therapeutic approach to Spinal Muscular Atrophy (SMA)

submit enquiry
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals

University: University of St Andrews

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

The genetic cause of SMA is deletion of the SMN 1 gene affecting Survival Motor Neurone (SMN) expression, but precisely how low or reduced levels of SMN lead to SMA is not properly understood. Efforts to decipher the complex cellular pathology of SMA are complicated by the fact that the SMN protein has numerous functions within the cell; an additional and poorly understood phenomenon is that while it is thought that many cell types are affected in SMA, motor neurons appear particularly sensitive to low levels of SMN protein.

SMN has been implicated in transport of mRNA in neural cells for local translation. We previously identified microtubule-dependant mobile vesicles rich in SMN and the splicing factor SmB, a member of the Sm protein family, in neural cells. By comparing the proteome of SmB to that of SmN, a neural-specific Sm protein, we have shown that the essential neural protein neurochondrin (NCDN) interacts with Sm proteins and SMN in the context of mobile vesicles in neurites. NCDN has roles in protein localisation in neural cells, and in maintenance of cell polarity. NCDN is required for the correct localisation of SMN, suggesting they may both be required for formation and transport of trafficking vesicles.

NCDN provides a potential therapeutic target for SMA together with, or in place of, those targeting SMN expression.Therapeutics increasing NCDN expression could prove useful in treating SMA, and we have developed NCDN modulators for use in the treatment and/or prevention of spinal muscular atrophy.

Key Benefits:

  • Neurochondrin modulators have the potential to treat and/or prevent SMA, however further development work is required

Applications:

  • A novel thereapeutic approach to treat SMA and other neurodegenerative disorders

IP Status:

The University filed a UK patent application GB1717433.2 on 29 June 2017. We would welcome enquiries from commercial parties interested in developing this potential SMA therapy further.

Enquiry

Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities


Register Now for University Technology.com Alerts


Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.